{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:35:46Z","timestamp":1791999346428,"version":"4.4.0"},"reference-count":51,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The present study explored the acceptability of psilocybin\u2010assisted group therapy from the perspective of patients with cancer and depression who participated in a clinical trial assessing the safety and efficacy of this novel intervention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Guided by the conceptual framework of acceptability, the authors conducted semi\u2010structured interviews with participants of the psilocybin trial. Data were analyzed using template and thematic analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Participants\u2019 (<jats:italic>n<\/jats:italic>\u00a0=\u00a028) perspectives on the acceptability of the group and simultaneous sessions was generally positive, both in terms of safety and efficacy: first, the groups contributed to increase participants\u2019 sense of safety and preparedness as they were engaging in the therapy; and second, the groups fostered a sense of connection and of belonging, which served to enrich and deepen the meaning of participants\u2019 experience, ultimately opening a dimension of self\u2010transcendence and compassion. Other subthemes related to factors influencing the acceptability of the group approach included: 1) the importance of the therapeutic framework, 2) the complementary value of individual sessions, 3) disruptive factors related to the group and\/or simultaneous setting, and 4) opportunities and challenges related to group size and how to structure interactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study enhances understanding of what promotes acceptability of the psilocybin\u2010assisted therapy group model for the treatment of MDD in cancer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Plain Language Summary<\/jats:title><jats:p>\n<jats:list list-type=\"bullet\">\n<jats:list-item><jats:p>We conducted exit interviews with participants of a phase 2 trial of psilocybin\u2010assisted therapy (PAT) conducted in a community cancer center, to assess the acceptability of a novel psilocybin delivery model combining simultaneous individual therapy and group sessions.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Our findings support the acceptability of this intervention and suggest that in addition to being feasible, it might also enhance participants\u2019 perceived safety and efficacy compared to uniquely individual or group delivery models of PAT.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Our analysis highlights critical factors conditioning acceptability and suggests new ways PAT may be scaled and integrated into cancer care.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.35024","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T03:01:14Z","timestamp":1702868474000},"page":"1147-1157","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Acceptability of psilocybin\u2010assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis"],"prefix":"10.1002","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3716-6736","authenticated-orcid":false,"given":"Yvan","family":"Beaussant","sequence":"first","affiliation":[{"name":"Department of Psychosocial Oncology and Palliative Care Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"},{"name":"Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2452-6632","authenticated-orcid":false,"given":"Elise","family":"Tarbi","sequence":"additional","affiliation":[{"name":"Department of Psychosocial Oncology and Palliative Care Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"},{"name":"Department of Nursing University of Vermont  Burlington Vermont USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1880-0079","authenticated-orcid":false,"given":"Kabir","family":"Nigam","sequence":"additional","affiliation":[{"name":"Harvard Medical School  Boston Massachusetts USA"},{"name":"Department of Psychiatry Brigham and Women\u2019s Hospital  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skye","family":"Miner","sequence":"additional","affiliation":[{"name":"Department of Medical Humanities and Bioethics College of Medicine University of Arkansas for Medical Sciences  Little Rock Arkansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Sager","sequence":"additional","affiliation":[{"name":"Department of Psychosocial Oncology and Palliative Care Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"},{"name":"Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8928-4051","authenticated-orcid":false,"given":"Justin J.","family":"Sanders","sequence":"additional","affiliation":[{"name":"Department of Family Medicine McGill University  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ljuslin","sequence":"additional","affiliation":[{"name":"Harvard Medical School  Boston Massachusetts USA"},{"name":"University of Geneva  Geneva Switzerland"},{"name":"Palliative Medicine Division Department of Rehabilitation and Geriatrics Geneva University Hospitals  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0141-7874","authenticated-orcid":false,"given":"Benjamin","family":"Gu\u00e9rin","sequence":"additional","affiliation":[{"name":"Department of Philosophy University of Franche Comt\u00e9  Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Thambi","sequence":"additional","affiliation":[{"name":"Sunstone Therapies  Rockville Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Tulsky","sequence":"additional","affiliation":[{"name":"Department of Psychosocial Oncology and Palliative Care Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"},{"name":"Harvard Medical School  Boston Massachusetts USA"},{"name":"Department of Medicine Brigham and Women\u2019s Hospital  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0727-6822","authenticated-orcid":false,"given":"Manish","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Sunstone Therapies  Rockville Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"SEER data 2020.Cancer of Any Site \u2010 Cancer Stat Facts. Accessed January 2 2020.https:\/\/seer.cancer.gov\/statfacts\/html\/all.html"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/pon.3409"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(00)02821\u2010x"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2006.07.016"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.22.2907"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1017\/s0033291709992285"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pon.3840"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.46.2101"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd007503.pub2"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269216310380764"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2215\u20100366(14)70313\u2010x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.116"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675512"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675513"},{"key":"e_1_2_9_16_1","article-title":"The therapeutic potential of psychedelic\u2010assisted therapies for symptom control in patients diagnosed with serious illness: a systematic review","author":"Maia LO","year":"2022","journal-title":"J Pain Symptom Manag"},{"key":"e_1_2_9_17_1","volume-title":"COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment\u2010resistant Depression","author":"COMPASS Pathways","year":"2018"},{"key":"e_1_2_9_18_1","unstructured":"Businesswire.FDA grants Breakthrough Therapy Designation to Usona Institute\u2019s psilocybin program for major depressive disorder.2019. Accessed August 8 2021.https:\/\/www.businesswire.com\/news\/home\/20191122005452\/en\/FDA\u2010grants\u2010Breakthrough\u2010Therapy\u2010Designation\u2010to\u2010Usona\u2010Institutes\u2010psilocybin\u2010program\u2010for\u2010major\u2010depressive\u2010disorder"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2019.0603"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2019.12.112"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100538"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211064720"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.12097"},{"key":"e_1_2_9_24_1","article-title":"Assessment of psilocybin therapy for patients with cancer and major depression disorder","author":"Agrawal M","year":"2023","journal-title":"JAMA Oncol"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913\u2010017\u20102031\u20108"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/14780887.2014.955224"},{"key":"e_1_2_9_27_1","first-page":"289","article-title":"Qualitative analysis: how to begin making sense","volume":"14","author":"Miller WL","year":"1994","journal-title":"Fam Pract Res J"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005053\u2010196312000\u201000007"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050324516683325"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049732315617444"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.11.046"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/00221678211022949"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213\u2010022\u201006187\u20105"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.1c00020"},{"key":"e_1_2_9_35_1","article-title":"Experiences of psilocybin treatment for clinical conditions: a qualitative meta\u2010synthesis","author":"Crowe M","year":"2023","journal-title":"Int J Mental Health Nurs"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2014.9427"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2017.07.029"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.11086"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.77.1097"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31539"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcbs.2019.11.002"},{"key":"e_1_2_9_42_1","article-title":"Ritualization as alternative approach to the spiritual dimension of palliative care: a concept analysis","author":"Weegen K","year":"2019","journal-title":"J Relig Health"},{"key":"e_1_2_9_43_1","article-title":"Chaplaincy and psychedelic\u2010assisted therapy: opportunities and barriers","volume":"42","author":"Beachy J","year":"2022","journal-title":"Reflective Pract"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2019.04.009"},{"key":"e_1_2_9_45_1","article-title":"On programming psychedelic experiences","volume":"5","author":"Metzner R","year":"1967","journal-title":"Psychedelic Rev"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2019.1593559"},{"key":"e_1_2_9_47_1","unstructured":"Chacruna Institute for Psychedelic Plant Medicines.Guide to RFRA and Best Practices for Psychedelic Plant Medicine Churches2021. Accessed June 30 2023.https:\/\/chacruna.net\/guide_rfra_best_practices_psychedelic_churches\/"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40309\u2010022\u201000199\u20102"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2009.11.015"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.3151"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(11)70002\u2010x"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/ev.1427"}],"updated-by":[{"DOI":"10.1002\/cncr.70003","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000}}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.35024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:07:42Z","timestamp":1760292462000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.35024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1002\/cncr.35024"],"URL":"https:\/\/doi.org\/10.1002\/cncr.35024","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]},"assertion":[{"value":"2023-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}